Significantly inhibits Escherichia coli, Gardnerella vaginalis, and Candida albicans, while demonstrating strong adherence to vaginal epithelial cells in females. Animal experiments show that LCr86 markedly reduces vaginal inflammation induced by various bacteria in mice with vaginitis.

Exhibits strong inhibitory effects against pathogenic bacteria such as Gardnerella vaginalis, Atopobium vaginae, and Candida albicans, establishing a defensive barrier against pathogenic bacteria by adhering to vaginal epithelial cells, thereby alleviating bacterial vaginosis caused by these pathogens. Its metabolites (bacteriocins, lactic acid, hydrogen peroxide, etc.) possess potent antibacterial and anti-inflammatory properties, assisting in improving the vaginal environment.

Verified through population trials to possess significant anti-vaginitis capabilities. Additionally, N13 effectively adheres to vaginal epithelial cells, inhibiting common pathogens such as Escherichia coli, Salmonella, and Staphylococcus aureus.

Demonstrates significant therapeutic effects against vaginitis and possesses the ability to prevent recurrence. It broadly and efficiently inhibits pathogens such as Candida albicans, Escherichia coli, Staphylococcus aureus, Gardnerella vaginalis, and Salmonella.

Produces metabolites including phosphoric acid, peptidoglycans, lactobacillin, reuterin, and hydrogen peroxide, aiding in the formation of spatial occupation and creation of a vaginal acidic environment. This inhibits pathogen proliferation and prevents pathogen adherence to vaginal epithelial cells. Results from mouse experiments confirm LR08's ability to improve vaginal health and effectively treat vaginitis.